BridgeBio licenses acoramidis to Bayer for EU rights; up to $310M milestones plus royalties

BridgeBio Pharma, Inc.

Eidos grants Bayer exclusive license to develop/commercialize acoramidis (AG10) for ATTR amyloidosis in EU and European Patent Organization.
BridgeBio eligible for up to $310M in upfront, regulatory, and sales milestone payments through 2026.
Additional payments subject to achievement of further sales milestones.
Tiered royalties starting in low-thirties percent on net sales in Licensed Territory.
Agreement subject to antitrust clearance; termination rights for material breach, insolvency, or Bayer convenience (270 days' notice).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BridgeBio Pharma, Inc. entered into Agreement with Bayer Consumer Care AG valued at up to $310 million in upfront, regulatory, and sales milestone payments (effective 2024-03-01).

Action: entry
Agreement: license
Counterparty: Bayer Consumer Care AG
Value: up to $310 million in upfront, regulatory, and sales milestone payments
Effective: 2024-03-01

Exact text from the filing

On March 1, 2024, certain subsidiaries of BridgeBio Pharma, Inc. (the “Company”), including Eidos Therapeutics, Inc. (“Eidos”), BridgeBio International GmbH and BridgeBio Europe B.V., entered into an exclusive license agreement (the “Agreement”) with Bayer Consumer Care AG, a wholly-owned subsidiary of Bayer AG (“Bayer”), to develop and commercialize acoramidis as a treatment for transthyretin amyloidosis in the European Union and all member states of the European Patent Organization (the “Licensed Territory”).

View on SEC.gov

737 material agreements filed in the last 30 days. Browse all material agreements →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-010920

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.